E. Eric Tokat, Partner, is Co-President of Investment Banking at Centerview Partners. He is a founding member of Centerview's Healthcare practice. During his career, Mr. Tokat advised numerous clients on a broad range of strategic advisory assignments and transactions exceeding $350 billion in value across developed and emerging markets.
Mr. Tokat’s recent life sciences transactions include:
2020: $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
- 2023: $11bn sale of Prometheus Biosciences to Merck; $2.9bn sale of ProventionBio to Sanofi; $2bn sale of Bellus Health to GSK; up to $1.8bn sale of Cincor Pharma to AstraZeneca; up to $1.5bn acquisition of Amryt Pharma by Chiesi; up to $1.2bn sale of Albireo Pharma to Ipsen
- 2022: $12.5bn sale of Biohaven to Pfizer with simultaneous spin of Neuroscience assets into a new publicly traded company; Sale of Imago BioSciences to Merck for $1.35bn; Sale of Akouos to Lilly for up to $600M; Sale of Oyster Point Pharma to Viatris for up to $500M; Sale of MiroBio to Gilead for $405M; Sale of ReViral Therapeutics to Pfizer for $525M; Sale of DSJ Antibodies to Abbvie for $255M; Sale of Checkmate Pharmaceuticals to Regeneron for $250M; Sale of Tmunity to Kite Pharma/Gilead
- 2021: Sale of Amunix Pharmaceuticals to Sanofi for $1bn Upfront and $225mm in Milestones; $6.7bn acquisition of Arena Pharmaceuticals by Pfizer; $2.3bn sale of Trillium Therapeutics to Pfizer; Up to $2bn sale of Vividion Therapeutics to Bayer AG; $1.7bn sale of Constellation Pharmaceuticals to Morphosys AG; $1.9bn sale of Pandion Therapeutics to Merck; $4.6bn sale of Cantel Medical to Steris; Sale of Lengo Therapeutics to Blueprint Medicines for up to $465M; Sale of Sanifit to Vifor Pharma for up to €375M; Pfizer’s spin out of select Autoimmune assets and creation of Priovant; $200M investment in Immunovant by Roivant
- 2020: $1bn sale of Prevail Therapeutics to Eli Lilly; $2.75bn sale of VelosBio to Merck; $2.9bn sale of Eidos to BridgeBio; $650M sale of Biospecifics to Endo; Up to $1.75bn sale of exclusive option to acquire Pionyr Immunotherapeutics to Gilead; Merck’s spin off of Organon
- 2019: ArQule's $2.7bn sale to Merck; Synthorx's $2.5bn sale to Sanofi; Achillion's up to $1.2bn sale to Alexion; Ra Pharma's $2.5bn sale to UCB S.A., Exact Sciences’ $2.8bn acquisition of Genomic Health; Peloton Therapeutics’ up to $2.2bn sale to Merck; Spark Therapeutics’ $4.8bn sale to Roche; Ipsen’s up to $1.3bn acquisition of Clementia Pharmaceuticals
- 2018: Merck’s €3.25bn acquisition of Antellia; Syntimmune’s up to $1.2bn sale to Alexion; Pfizer’s consumer JV with GSK; Pfizer’s spin out of CAR-T assets and creation of Allogene; Pfizer’s spin out of Neuroscience assets and creation of Cerevel Therapeutics; Synergy Pharmaceutical’s sale to Bausch Health
- 2017: Kite Pharma’s $12bn sale to Gilead; Valeant’s $1bn sale of Dendreon to Sanpower Group; China Regenerative Medicine’s acquisition of Obagi Medical from Valeant
- 2016: Pfizer’s $14bn acquisition of Medivation and $5bn acquisition of Anacor; Raptor’s $1bn sale to Horizon; Mylan’s $10bn acquisition of Meda
- 2015: Salix’s $16bn sale to Valeant; Dyax’s $6bn sale to Shire; Achillion's up to $1bn WW HCV collaboration with and $225m equity investment by J&J; Dendreon’s sale to Valeant
- 2014: Algeta’s $3bn sale to Bayer; Cadence Pharmaceuticals’ $1bn sale to Mallinckrodt; Mylan’s $5bn acquisition of Abbott’s Branded Generics business in an inversion transaction and $1bn acquisition of FamyCare; BioAlliance Pharma’s merger with Topotarget to form Onxeo
- 2013: Trius Therapeutics’ up to $1bn sale to Cubist; Optimer Pharmaceuticals’ up to $1bn sale to Cubist; Phillip Morris’ joint venture with Mitsubishi Tanebe and subsequent joint acquisition of Medicago
- 2012: Pfizer’s $12bn sale of its Nutrition Business to Nestlé
- 2011: OSI’s $4bn sale to Astellas; Ventas’ $7bn acquisition of NHP
Mr. Tokat’s other healthcare transactions include: Pfizer’s $68bn acquisition of Wyeth; $33bn LBO of HCA; AstraZeneca's $15bn acquisition of MedImmune; Celgene’s $3bn acquisition of Pharmion; New River Pharmaceuticals’ $3bn sale to Shire; ICOS' $2bn sale to Eli Lilly; LifeCell's $2bn sale to Kinetic Concepts; Cougar Biotechnology's $1bn sale to J&J; Haemonetics' acquisition of Pall Corp.'s Blood Filtration Business; Thirdwave Technologies' sale to Hologic; Virochem’s sale to Vertex; the LBO of Symbion; Intercell’s acquisition of Iomai; American Bioscience’s merger with American Pharmaceutical Partners.
Mr. Tokat serves on a number of not-for-profit boards, including: a trustee at the Brookings Institution, chair of the Audit Committee at the IRC (International Rescue Committee), and vice chair of the Board of the Columbia University's Mailman School of Public Health. He is a member of the Council on Foreign Relations.
Mr. Tokat received his BA from Bogazici University and MIA from Columbia University.